<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770950</url>
  </required_header>
  <id_info>
    <org_study_id>81758</org_study_id>
    <nct_id>NCT02770950</nct_id>
  </id_info>
  <brief_title>Zushima Plaster for Treating Knee Osteoarthritis</brief_title>
  <official_title>Zushima Plaster for Patients in Knee Osteoarthritis: a Random, Positive Drug Controlled, Multi-center Clinical Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Municipal Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gansu Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Beijing Military Area</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further evaluate the clinical efficacy and safety of Zushima
      plaster for patients in knee osteoarthrosis post-marketing.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of Visual Analogue Scale (VAS) pain score from baseline to posttreatment</measure>
    <time_frame>Week 2.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of Patient's global assessment of disease activity from baseline to posttreatment</measure>
    <time_frame>Week 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of WOMAC Osteoarthritis Index from baseline to posttreatment</measure>
    <time_frame>Week 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Short Form 36 Questionnaire (SF-36) score from baseline to posttreatment</measure>
    <time_frame>Week 2.</time_frame>
    <description>The SF-36 is a generic instrument to assess health-related quality of life. It consists of 36 questions and assesses 8 dimensions: physical functioning, role physical, pain index, general health, vitality, social functioning, role emotional, and mental health index. It also provides 2 summary measures of physical and mental components. The SF-36 score ranges from 0 to 100, with higher scores indicating better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Erythrocyte Sedimentation rate (ESR) from baseline to posttreatment</measure>
    <time_frame>Week 2.</time_frame>
    <description>ESR, also called a sedimentation rate, is the rate at which red blood cells sediment in a period of one hour. It is a non-specific measure of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of C-reactive protein (CRP) from baseline to posttreatment</measure>
    <time_frame>Week 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of knee musculoskeletal ultrasound (MSUS) from baseline to posttreatment</measure>
    <time_frame>Week 2.</time_frame>
    <description>MSUS had wisely using in rheumatology practice and research. MSUS includes synovitis classification, synovial hyperplasia classification, articular cavity effusion and bone erosion classification. Specific as follows: Synovitis classification: 0 level, no doppler signal; level 1: three independent point or 2 successive or 1 and 2 in independent dot doppler signal; level 2: doppler signal &lt; 50% of the synovial membrane area; level 3 doppler signal is the synovium in &gt; 50% of the area. Synovial hyperplasia classification: 0 level, no synovial hyperplasia; level 1: synovial hyperplasia of mild, not more than bone surface high attachment; level 2: synovial hyperplasia more than bone surface high wire, but not more than the backbone; level 3: synovial hyperplasia more than bone surface peak wires, and extends along the backbone of the side. Articular cavity effusion and bone erosion classification: adopt binary evaluation, namely 0: normal, 1: abnormal.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.
Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.
Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indometacin Cataplasms will be used topically on the knee for 24h per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zushima plaster with high dose</intervention_name>
    <description>Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.</description>
    <arm_group_label>High dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zushima plaster with low dose</intervention_name>
    <description>Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.</description>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indometacin Cataplasms</intervention_name>
    <description>Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.</description>
    <arm_group_label>Controlled group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 40-75;

          -  Unilateral or bilateral knee OA, confirmed radiographically;

          -  Patients taking oral NSAIDs prior to the breakthrough period will be permitted;

          -  VAS pain score is or above 20mm.

        Exclusion Criteria:

          -  Knee is swollen and hot;

          -  Allergic to any ingredient in Girald Daphne Bark Plaster (Girald Daphne Bark,
             Lithargite, Linseed oil, Red lead) ;

          -  Congestive Heart Failure and Edema;

          -  Advanced renal disease;

          -  Knee joint skin is burst or skin disease or allergies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quan Jiang, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guang'anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>January 13, 2018</last_update_submitted>
  <last_update_submitted_qc>January 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Juan Jiao</investigator_full_name>
    <investigator_title>Attending Doctor</investigator_title>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

